Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience

Jeffrey A Berinstein; Taylor Karl; Anish Patel; Michael Dolinger; Terrence A Barrett; Waseem Ahmed; Ben Click; Calen A Steiner; David Dulaney; Jake Levine; Syed Adeel Hassan; Courtney Perry; Deborah Flomenhoft; Ryan C Ungaro; Elliot M Berinstein; Jessica Sheehan; Shirley Cohen-Mekelburg; Randolph E Regal; Ryan W Stidham; Shrinivas Bishu; Jean-Frederic Colombel; Peter D R Higgins

doi:10.14309/ajg.0000000000002674

Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience

Jeffrey A Berinstein, Taylor Karl, Anish Patel, Michael Dolinger, Terrence A Barrett, Waseem Ahmed, Ben Click, Calen A Steiner, David Dulaney, Jake Levine, Syed Adeel Hassan, Courtney Perry, Deborah Flomenhoft, Ryan C Ungaro, Elliot M Berinstein, Jessica Sheehan, Shirley Cohen-Mekelburg, Randolph E Regal, Ryan W Stidham, Shrinivas BishuJean-Frederic Colombel, Peter D R Higgins

Brooke Army Medical Center (BAMC)

Research output: Contribution to journal › Article › peer-review

Abstract

INTRODUCTION: A significant proportion of patients with acute severe ulcerative colitis (ASUC) require colectomy.

METHODS: Patients with ASUC treated with upadacitinib and intravenous corticosteroids at 5 hospitals are presented. The primary outcome was 90-day colectomy rate. Secondary outcomes included frequency of steroid-free clinical remission, adverse events, and all-cause readmissions.

RESULTS: Of the 25 patients with ASUC treated with upadacitinib, 6 (24%) patients underwent colectomy, 15 (83%) of the 18 patients with available data and who did not undergo colectomy experienced steroid-free clinical remission (1 patient did not have complete data), 1 (4%) patient experienced a venous thromboembolic event, while 5 (20%) patients were readmitted.

DISCUSSION: Upadacitinib along with intravenous corticosteroids may be an effective treatment for ASUC.

Original language	English
Journal	American Journal of Gastroenterology
DOIs	https://doi.org/10.14309/ajg.0000000000002674
State	E-pub ahead of print - 27 Mar 2024

Access to Document

10.14309/ajg.0000000000002674

Cite this

Berinstein, J. A., Karl, T., Patel, A., Dolinger, M., Barrett, T. A., Ahmed, W., Click, B., Steiner, C. A., Dulaney, D., Levine, J., Hassan, S. A., Perry, C., Flomenhoft, D., Ungaro, R. C., Berinstein, E. M., Sheehan, J., Cohen-Mekelburg, S., Regal, R. E., Stidham, R. W., ... Higgins, P. D. R. (2024). Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience. American Journal of Gastroenterology. Advance online publication. https://doi.org/10.14309/ajg.0000000000002674

@article{e4376fd170c946b195ec67511144c949,

title = "Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience",

abstract = "INTRODUCTION: A significant proportion of patients with acute severe ulcerative colitis (ASUC) require colectomy.METHODS: Patients with ASUC treated with upadacitinib and intravenous corticosteroids at 5 hospitals are presented. The primary outcome was 90-day colectomy rate. Secondary outcomes included frequency of steroid-free clinical remission, adverse events, and all-cause readmissions.RESULTS: Of the 25 patients with ASUC treated with upadacitinib, 6 (24%) patients underwent colectomy, 15 (83%) of the 18 patients with available data and who did not undergo colectomy experienced steroid-free clinical remission (1 patient did not have complete data), 1 (4%) patient experienced a venous thromboembolic event, while 5 (20%) patients were readmitted.DISCUSSION: Upadacitinib along with intravenous corticosteroids may be an effective treatment for ASUC.",

author = "Berinstein, {Jeffrey A} and Taylor Karl and Anish Patel and Michael Dolinger and Barrett, {Terrence A} and Waseem Ahmed and Ben Click and Steiner, {Calen A} and David Dulaney and Jake Levine and Hassan, {Syed Adeel} and Courtney Perry and Deborah Flomenhoft and Ungaro, {Ryan C} and Berinstein, {Elliot M} and Jessica Sheehan and Shirley Cohen-Mekelburg and Regal, {Randolph E} and Stidham, {Ryan W} and Shrinivas Bishu and Jean-Frederic Colombel and Higgins, {Peter D R}",

note = "Copyright {\textcopyright} 2024 by The American College of Gastroenterology.",

year = "2024",

month = mar,

day = "27",

doi = "10.14309/ajg.0000000000002674",

language = "English",

journal = "American Journal of Gastroenterology",

issn = "0002-9270",

}

Berinstein, JA, Karl, T, Patel, A, Dolinger, M, Barrett, TA, Ahmed, W, Click, B, Steiner, CA, Dulaney, D, Levine, J, Hassan, SA, Perry, C, Flomenhoft, D, Ungaro, RC, Berinstein, EM, Sheehan, J, Cohen-Mekelburg, S, Regal, RE, Stidham, RW, Bishu, S, Colombel, J-F & Higgins, PDR 2024, 'Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience', American Journal of Gastroenterology. https://doi.org/10.14309/ajg.0000000000002674

TY - JOUR

T1 - Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis

T2 - A Multicenter Experience

AU - Berinstein, Jeffrey A

AU - Karl, Taylor

AU - Patel, Anish

AU - Dolinger, Michael

AU - Barrett, Terrence A

AU - Ahmed, Waseem

AU - Click, Ben

AU - Steiner, Calen A

AU - Dulaney, David

AU - Levine, Jake

AU - Hassan, Syed Adeel

AU - Perry, Courtney

AU - Flomenhoft, Deborah

AU - Ungaro, Ryan C

AU - Berinstein, Elliot M

AU - Sheehan, Jessica

AU - Cohen-Mekelburg, Shirley

AU - Regal, Randolph E

AU - Stidham, Ryan W

AU - Bishu, Shrinivas

AU - Colombel, Jean-Frederic

AU - Higgins, Peter D R

PY - 2024/3/27

Y1 - 2024/3/27

N2 - INTRODUCTION: A significant proportion of patients with acute severe ulcerative colitis (ASUC) require colectomy.METHODS: Patients with ASUC treated with upadacitinib and intravenous corticosteroids at 5 hospitals are presented. The primary outcome was 90-day colectomy rate. Secondary outcomes included frequency of steroid-free clinical remission, adverse events, and all-cause readmissions.RESULTS: Of the 25 patients with ASUC treated with upadacitinib, 6 (24%) patients underwent colectomy, 15 (83%) of the 18 patients with available data and who did not undergo colectomy experienced steroid-free clinical remission (1 patient did not have complete data), 1 (4%) patient experienced a venous thromboembolic event, while 5 (20%) patients were readmitted.DISCUSSION: Upadacitinib along with intravenous corticosteroids may be an effective treatment for ASUC.

AB - INTRODUCTION: A significant proportion of patients with acute severe ulcerative colitis (ASUC) require colectomy.METHODS: Patients with ASUC treated with upadacitinib and intravenous corticosteroids at 5 hospitals are presented. The primary outcome was 90-day colectomy rate. Secondary outcomes included frequency of steroid-free clinical remission, adverse events, and all-cause readmissions.RESULTS: Of the 25 patients with ASUC treated with upadacitinib, 6 (24%) patients underwent colectomy, 15 (83%) of the 18 patients with available data and who did not undergo colectomy experienced steroid-free clinical remission (1 patient did not have complete data), 1 (4%) patient experienced a venous thromboembolic event, while 5 (20%) patients were readmitted.DISCUSSION: Upadacitinib along with intravenous corticosteroids may be an effective treatment for ASUC.

U2 - 10.14309/ajg.0000000000002674

DO - 10.14309/ajg.0000000000002674

M3 - Article

C2 - 38275248

SN - 0002-9270

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

ER -

Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience

Abstract

Access to Document

Fingerprint

Cite this